Obermayer-Straub P, Strassburg C P, Manns M P
Medizinische Hochschule Hannover, Hannover, Germany.
Can J Gastroenterol. 2000 May;14(5):429-39. doi: 10.1155/2000/910107.
Cytochromes P450 (CYPs) and UDP-glucuronosyltransferases (UGTs) are targets of autoantibodies in several hepatic and extrahepatic autoimmune diseases. Autoantibodies directed against hepatic CYPs and UGTs were first detected by indirect immunofluorescence as antiliver and/or kidney microsomal antibodies. In autoimmune hepatitis (AIH) type 2, liver and/or kidney microsomal (LKM) type 1 autoantibodies are detected and are directed against CYP2D6. About 10% of AIH-2 sera further contain LKM-3 autoantibodies directed against family 1 UGTs. Chronic infections by hepatitis C virus and hepatitis delta virus may induce several autoimmune phenomena, and multiple autoantibodies are detected. Anti-CYP2D6 autoantibodies are detected in up to 4% of patients with chronic hepatitis C, and anti-CYP2A6 autoantibodies are detected in about 2% of these patients. In contrast, 14% of patients with chronic hepatitis delta virus infections generate anti-UGT autoantibodies. In a small minority of patients, certain drugs are known to induce immune-mediated, idiosyncratic drug reactions, also known as 'druginduced hepatitis'. Drug-induced hepatitis is often associated with autoantibodies directed against hepatic CYPs or other hepatic proteins. Typical examples are tienilic acid-induced hepatitis with anti-CYP2C9, dihydralazine hepatitis with anti-CYP1A2, halothane hepatitis with anti-CYP2E1 and anticonvulsant hepatitis with anti-CYP3A. Recent data suggest that alcoholic liver disease may be induced by mechanisms similar to those that are active in drug-induced hepatitis. Autoantibodies directed against several CYPs are further detected in sera from patients with the autoimmune polyglandular syndrome type 1. Patients with autoimmune polyglandular syndrome type 1 with hepatitis often develop anti-CYP1A2; patients with adrenal failure develop anti-CYP21, anti- CYP11A1 or CYP17; and patients with gonadal failure develop anti-CYP11A1 or CYP17. In idiopathic Addison disease, CYP21 is the major autoantigen.
细胞色素P450(CYPs)和尿苷二磷酸葡萄糖醛酸转移酶(UGTs)是几种肝脏和肝外自身免疫性疾病中自身抗体的靶标。针对肝脏CYPs和UGTs的自身抗体最初通过间接免疫荧光法作为抗肝和/或抗肾微粒体抗体被检测到。在2型自身免疫性肝炎(AIH)中,可检测到肝脏和/或肾脏微粒体(LKM)1型自身抗体,其针对细胞色素P450 2D6(CYP2D6)。约10%的AIH-2血清还含有针对1型UGT家族的LKM-3自身抗体。丙型肝炎病毒和丁型肝炎病毒的慢性感染可能诱发多种自身免疫现象,并可检测到多种自身抗体。在高达4%的慢性丙型肝炎患者中可检测到抗CYP2D6自身抗体,在约2%的此类患者中可检测到抗CYP2A6自身抗体。相比之下,14%的慢性丁型肝炎病毒感染患者会产生抗UGT自身抗体。在少数患者中,某些药物已知会诱发免疫介导的特异质性药物反应,也称为“药物性肝炎”。药物性肝炎通常与针对肝脏CYPs或其他肝脏蛋白的自身抗体相关。典型例子包括替尼酸诱发的肝炎伴抗CYP2C9、肼屈嗪肝炎伴抗CYP1A2、氟烷肝炎伴抗CYP2E1以及抗惊厥药肝炎伴抗CYP3A。最近的数据表明,酒精性肝病可能由与药物性肝炎中活跃的机制类似的机制诱发。在1型自身免疫性多腺体综合征患者的血清中还可检测到针对几种CYPs的自身抗体。1型自身免疫性多腺体综合征合并肝炎的患者常产生抗CYP1A2;肾上腺功能衰竭患者产生抗CYP21、抗CYP11A1或CYP17;性腺功能衰竭患者产生抗CYP11A1或CYP17。在特发性Addison病中,CYP21是主要自身抗原。